BGI Dx, Bioscience Genomics Ink NIPT Deal

 

UPDATE: Danaher Q3 Revenues Improve 4 Percent

 

Alnylam Stock Jumps on Positive Phase II ATTR Drug Data

 

Arrowhead Sued over Stock Drop Linked to Clinical Data on HBV Drug Candidate

 

With RNAi Screening Tech, Startup Recursion Aims to Repurpose Drugs for Rare Diseases

 

Arcturus Touts Dosing, Specificity of ATTR Drugs as They Move Toward Clinic

 

Nitto Denko Advances RNAi Fibrosis Drug into Phase Ib

 

Alnylam Presents Animal Data on siRNA Delivery via Inhalation, Adds PH1 to Pipeline

 

IP Update: Recent Patents Awarded to Alnylam, Quark, Qiagen, and More

 

NIAID Awards Consortium $6.5M to Investigate S. Aureus